Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

Video

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the background of the phase I/II study of carfilzomib as a replacement for bortezomib for multiple myeloma (MM) patients refractory to a bortezomib-containing combination regimen.

The idea for the trial, Berenson says, stemmed from the need for a proteasome inhibitor that could overcome resistance to bortezomib. Thirty-two patients were enrolled who had progressed on bortezomib or were within 12 weeks of the last dose. Patients then received a regimen replacing bortezomib with carfilzomib and continued with the other agents in the regimen without change in dosage or schedule.

Clinical benefit was seen in 75% of patients (complete response = 8.3%; very good partial response = 16.7%; partial response = 29.2%; minor response = 20.8%) while another 16.7% showed stable disease.

Berenson was surprised by these impressive results, as well as the safety data, and feels that carfilzomib will be a robust product for patients who fail bortezomib.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD